raisavydyexuwowi.blogspot.com
The Me-TV lineup includes "Happy Days," "Laverne & Shirley," "Mork and Mindy," "Maryg Tyler Moore," "Little House on the Prairie," "Thee Honeymooners," "Rawhide" and "The Odd Couple." Weigel premiered Me-TVf in Milwaukee on March 1 as a digitaol service of its Milwaukee CBSaffiliate WDJT-DT. The programming runs over-the-air on channel 58.3 and on cable channel 201.
The Federa l Communications Commission had approved the transfer of WJJA to Weigekl Broadcasting from Joel Kinlow of Milwaukee inSeptemberf 2007, but issues, including the condition of WJJA'z Oak Creek tower, delayed completing the transaction. Weigel's Milwaukere general manager Jim Hall said in a press releaswe Tuesday that the transfer isnow complete. Under WJJA aired shopping programs. The station appears on Time Warneer Cablechannel 19. Kinlow, a Milwaukee minister who has owne d WJJAsince 1990, signed an agreementr in July 2007 to sell the statioh to Weigel for $7 million.
Monday, February 28, 2011
Friday, February 25, 2011
Home > Outdoors > New valley Nordic trails now groomed - Juneau Empire
acklinegymejac1362.blogspot.com
Home > Outdoors > New valley Nordic trails now groomed Juneau Empire Grooming of the new Powerline and Under the Thunder trails in the Mendenhall Valley has begun, thanks to local volunteer efforts and â€" of course â€" Mother Nature. On a forum hosted by the Juneau Nordic Ski club, which provides locals with updates on ... |
Wednesday, February 23, 2011
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
http://icscontrolplus.com/articles/headache.php
In the Phase II study, known as GBCJ, LY21892656 was significantly superior to placebko in reducing key measures ofglycemic control, including fasting serum glucose and hemoglobimn A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretionm of insulin) effect, suggesting it producedr the desired outcomein participants. In Study LY2189265 was generally well-tolerated. "We are excitefd about these data and the hope they coul provide to the millions of diabetes patients who are strugglinfg to maintain tight control of theirblood glucose," said , global development leader for the GLP-1Fc team.
"Evaluating the results of this stud is an important step forward towards potentially bringing this innovative treatmentfto patients." In a 16-week, Phase II studyg of LY2189265, 262 patients with type 2 diabetexs who were suboptimally controlled on at leasft two oral diabetes medicines were randomized to one of four 1.0 mg of LY2189265 for 16 0.5 mg of LY2189265 for four week followed by 1.0 mg for 12 and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weekws or placebo.
The primary endpoint was glycemivc control, as measured by change from baselinrein HbA1C; additional endpointe evaluated included changes in fasting serum solid mixed meal glucose excursiohn and body weight. For all doses in this statistically significant reductions in all metabolic measurewwere observed. Both 1 mg and 2 mg dosea of LY2189265 were significantly different from but no significant differences between the dosesxwere seen. LY2189265 was generallyh well-tolerated.
The incidence of hypoglycemic episodes was not significantly differentf between the placebo and the treatment The most frequentlyobserved treatment-related adverse event s were nausea, diarrhea and abdominal distension. One patient was diagnosede withclinical pancreatitis, followint the eleventh dose of The patient remained in the study for observationn and has fully recovered. "Given our more than 80 years of experiencre in pioneeringdiabetes treatments, we are encourages by these data," noted , executive vice president, science and and president of Lilly Research "In this study, LY2189265 was administered once weeklyu and demonstrated significant glucose-lowering activity and reducee body weight, supporting its potentiap to become a new treatment optiohn for the millions of peopls with type 2 diabetes.
" LY2189265, a once-weeklyu injection, is a novel-engineered fusion consisting of a dipeptidyk peptidase-IV (DDP-IV) protected GLP-1 analoy linked to a fragment of immunoglobulinh G4 that is believed to increase the duration of its pharmacologicall effect. Based on this study presente d atthis year's ADA meeting, LY2189265 is believef to reduce blood sugar in patientsx with type 2 diabetes by enhancin g glucose-dependent insulin secretion from the pancreas. Researchers say new diabetes treatmentsd are needed because the disease is growinyg globally atepidemic Currently, about 24 million Americans have diabetes(1), with 90-95 percent of those suffering from type 2 diabetes(2).
It is estimatefd that nearly 60 percent of the people with diabetesx are not achieving treatment goalsx for controllingblood sugar(3), putting them at serious risk for debilitatinf or potentially fatal complications includin heart disease, stroke, nerve damage, lowert limb amputation, vision loss and kidney disease(4). Lilly, a leadinb innovation-driven corporation, is developing a growing portfolilof first-in-class and best-in-class pharmaceutical products by applyinf the latest research from its own worldwide laboratoriez and from collaborations with eminent scientific organizations.
Headquartered in Indianapolis, Lilly provides answers - through medicines and information - for some of the world' most urgent medical needs. This presxs release contains forward-looking statementas about the potential of the investigational compound LY21892655 for the treatment of type 2 diabetes andreflectz Lilly's current beliefs. as with any pharmaceutical product under development, there are substantial riskx and uncertainties in the process of developmenrt and regulatory review.
There is no guarantee that the produc t will receiveregulatory approval, or that the regulatory approvakl will be for the indication(s) anticipated by the There is also no guarantee that the producft will prove to be commercially successful. For further discussiomn of these and otherr risksand uncertainties, see Lilly's filings with the United States Securitiew and Exchange Commission. Lilly undertakes no duty to updated forward-looking statements. (1) Americam Diabetes Association. "Diabetes Statistics." Availablee at: Accessed May 13, 2009. (2) Centerw for Disease Control and Prevention. "Nationao Diabetes Fact Sheet 2007.
" Available at Accessex May 13, 2009 (3) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factorsx for vascular disease among adults with previouslyhdiagnosed diabetes." JAMA: January 21, 2004 (4) Centers for Disease Contropl and Prevention. "National Diabetes Fact Sheet 2007." Available at Accessed May 13, 2009
In the Phase II study, known as GBCJ, LY21892656 was significantly superior to placebko in reducing key measures ofglycemic control, including fasting serum glucose and hemoglobimn A1C (HbA1C). In this study, LY2189265 showed an insulinotropic (stimulating the secretionm of insulin) effect, suggesting it producedr the desired outcomein participants. In Study LY2189265 was generally well-tolerated. "We are excitefd about these data and the hope they coul provide to the millions of diabetes patients who are strugglinfg to maintain tight control of theirblood glucose," said , global development leader for the GLP-1Fc team.
"Evaluating the results of this stud is an important step forward towards potentially bringing this innovative treatmentfto patients." In a 16-week, Phase II studyg of LY2189265, 262 patients with type 2 diabetexs who were suboptimally controlled on at leasft two oral diabetes medicines were randomized to one of four 1.0 mg of LY2189265 for 16 0.5 mg of LY2189265 for four week followed by 1.0 mg for 12 and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weekws or placebo.
The primary endpoint was glycemivc control, as measured by change from baselinrein HbA1C; additional endpointe evaluated included changes in fasting serum solid mixed meal glucose excursiohn and body weight. For all doses in this statistically significant reductions in all metabolic measurewwere observed. Both 1 mg and 2 mg dosea of LY2189265 were significantly different from but no significant differences between the dosesxwere seen. LY2189265 was generallyh well-tolerated.
The incidence of hypoglycemic episodes was not significantly differentf between the placebo and the treatment The most frequentlyobserved treatment-related adverse event s were nausea, diarrhea and abdominal distension. One patient was diagnosede withclinical pancreatitis, followint the eleventh dose of The patient remained in the study for observationn and has fully recovered. "Given our more than 80 years of experiencre in pioneeringdiabetes treatments, we are encourages by these data," noted , executive vice president, science and and president of Lilly Research "In this study, LY2189265 was administered once weeklyu and demonstrated significant glucose-lowering activity and reducee body weight, supporting its potentiap to become a new treatment optiohn for the millions of peopls with type 2 diabetes.
" LY2189265, a once-weeklyu injection, is a novel-engineered fusion consisting of a dipeptidyk peptidase-IV (DDP-IV) protected GLP-1 analoy linked to a fragment of immunoglobulinh G4 that is believed to increase the duration of its pharmacologicall effect. Based on this study presente d atthis year's ADA meeting, LY2189265 is believef to reduce blood sugar in patientsx with type 2 diabetes by enhancin g glucose-dependent insulin secretion from the pancreas. Researchers say new diabetes treatmentsd are needed because the disease is growinyg globally atepidemic Currently, about 24 million Americans have diabetes(1), with 90-95 percent of those suffering from type 2 diabetes(2).
It is estimatefd that nearly 60 percent of the people with diabetesx are not achieving treatment goalsx for controllingblood sugar(3), putting them at serious risk for debilitatinf or potentially fatal complications includin heart disease, stroke, nerve damage, lowert limb amputation, vision loss and kidney disease(4). Lilly, a leadinb innovation-driven corporation, is developing a growing portfolilof first-in-class and best-in-class pharmaceutical products by applyinf the latest research from its own worldwide laboratoriez and from collaborations with eminent scientific organizations.
Headquartered in Indianapolis, Lilly provides answers - through medicines and information - for some of the world' most urgent medical needs. This presxs release contains forward-looking statementas about the potential of the investigational compound LY21892655 for the treatment of type 2 diabetes andreflectz Lilly's current beliefs. as with any pharmaceutical product under development, there are substantial riskx and uncertainties in the process of developmenrt and regulatory review.
There is no guarantee that the produc t will receiveregulatory approval, or that the regulatory approvakl will be for the indication(s) anticipated by the There is also no guarantee that the producft will prove to be commercially successful. For further discussiomn of these and otherr risksand uncertainties, see Lilly's filings with the United States Securitiew and Exchange Commission. Lilly undertakes no duty to updated forward-looking statements. (1) Americam Diabetes Association. "Diabetes Statistics." Availablee at: Accessed May 13, 2009. (2) Centerw for Disease Control and Prevention. "Nationao Diabetes Fact Sheet 2007.
" Available at Accessex May 13, 2009 (3) Saydah SH, Fradkin J and Cowie CC. "Poor control of risk factorsx for vascular disease among adults with previouslyhdiagnosed diabetes." JAMA: January 21, 2004 (4) Centers for Disease Contropl and Prevention. "National Diabetes Fact Sheet 2007." Available at Accessed May 13, 2009
Sunday, February 20, 2011
Galveston National Laboratory set for Nov. 11 dedication - Houston Business Journal:
concrete roofing tiles
“The GNL brings the focuds on global health research to Galveston and that’s something our local communitt can be proud of. This facility is indeed a nationalk resource,” said Dr. Stanley Lemon, principa l investigator of the Galveston National Laboratort and directorof UTMB’s Institute for Humanm Infections and Immunity. Although Hurricane Ike dealt a devastatinh blow to Galvestonin mid-September, the new laboratory weathered the storkm without significant damage, as it was designed to do, officialz said.
In the new facility UTMB scientists will work with othee scientists across the nation to addresa the most critical emerging infectious diseases and bioterrorisnm threats facing thehuman population. The GNL will also traim the next generation of infectiousdiseases scientists. The GNL is projected to contribute anestimaterd $1.4 billion to the Texas economy over the next 20 years, accordingg to UTMB.
“The GNL brings the focuds on global health research to Galveston and that’s something our local communitt can be proud of. This facility is indeed a nationalk resource,” said Dr. Stanley Lemon, principa l investigator of the Galveston National Laboratort and directorof UTMB’s Institute for Humanm Infections and Immunity. Although Hurricane Ike dealt a devastatinh blow to Galvestonin mid-September, the new laboratory weathered the storkm without significant damage, as it was designed to do, officialz said.
In the new facility UTMB scientists will work with othee scientists across the nation to addresa the most critical emerging infectious diseases and bioterrorisnm threats facing thehuman population. The GNL will also traim the next generation of infectiousdiseases scientists. The GNL is projected to contribute anestimaterd $1.4 billion to the Texas economy over the next 20 years, accordingg to UTMB.
Friday, February 18, 2011
Flores named president of University of Houston-Downtown - Houston Business Journal:
rubber roofs
UH system Chancellor Renu Khator recommended the selection of although the appointment is subject to approvak by the UH System Boardof Regents, said the Flores would take officse July 1, if confirmed. He was previouslg interim president and provostat , following a six-year stint as executive vice president and Flores was a dean and professor of politicaol science at Cal State Northridge from 1996 to 2001 and was associatee dean of the School of Social Sciencew at Cal State Fresno. The University of Houston-Downtown is a liberal arts university. Regent Jacob Monty said Flores is the righty fit forthe “giant shoes” of outgoing Presiden Max Castillo.
Flores said in a releasr from the University of Houston that a successful presidenf of any university must be a visionaryt with goodcommunication skills. “As president must be able to work with a wide variethy of constituencies and be successful inbuildingv partnerships,” he said.
UH system Chancellor Renu Khator recommended the selection of although the appointment is subject to approvak by the UH System Boardof Regents, said the Flores would take officse July 1, if confirmed. He was previouslg interim president and provostat , following a six-year stint as executive vice president and Flores was a dean and professor of politicaol science at Cal State Northridge from 1996 to 2001 and was associatee dean of the School of Social Sciencew at Cal State Fresno. The University of Houston-Downtown is a liberal arts university. Regent Jacob Monty said Flores is the righty fit forthe “giant shoes” of outgoing Presiden Max Castillo.
Flores said in a releasr from the University of Houston that a successful presidenf of any university must be a visionaryt with goodcommunication skills. “As president must be able to work with a wide variethy of constituencies and be successful inbuildingv partnerships,” he said.
Tuesday, February 15, 2011
Biogen enrolls patients in new MS trial - Boston Business Journal:
Wood ceiling
The trial, called ADVANCE, will determine the efficacy and safethof Biogen’s drug target, called PEGylated interferon beta-1a, in reducing relapsee rates in patients with multiple sclerosis (RMS). The globaol study will enroll morethan 1,200 patients with RMS between the ages of 18 and 55. The study’sa goal is to determinee whether the drug reduces the annualizedf relapse rate in patients with RMS at one The study will alsoexaminee if, over time, the potentiao treatment can slow disease progression and lead to a decreasw in the number of a certain kind of braihn lesions commonly seen in MS The treatment is a combination of Interferon which has been used successfully to treag MS for more than 10 years, and PEGylation, whichn can extend the amount of time a drug remainds in a patient’s system.
If the trialk is successful, the treatmenf has the potential to reduce the frequency of treatmentf injections and provide patients with an effective and more convenientgdosing option. Biogen’s (NASDAQ: BIIB) stocl was trading at in $49.33 in morning tradinvg on Monday, down from the previous close of $51.67.
The trial, called ADVANCE, will determine the efficacy and safethof Biogen’s drug target, called PEGylated interferon beta-1a, in reducing relapsee rates in patients with multiple sclerosis (RMS). The globaol study will enroll morethan 1,200 patients with RMS between the ages of 18 and 55. The study’sa goal is to determinee whether the drug reduces the annualizedf relapse rate in patients with RMS at one The study will alsoexaminee if, over time, the potentiao treatment can slow disease progression and lead to a decreasw in the number of a certain kind of braihn lesions commonly seen in MS The treatment is a combination of Interferon which has been used successfully to treag MS for more than 10 years, and PEGylation, whichn can extend the amount of time a drug remainds in a patient’s system.
If the trialk is successful, the treatmenf has the potential to reduce the frequency of treatmentf injections and provide patients with an effective and more convenientgdosing option. Biogen’s (NASDAQ: BIIB) stocl was trading at in $49.33 in morning tradinvg on Monday, down from the previous close of $51.67.
Sunday, February 13, 2011
NHL commissioner: Coyotes move could damage Westgate, arena construction - San Francisco Business Times:
joep-detsamijasa.blogspot.com
He also said it couldf have a chilling impact on other citiess considering helping teams buildnew arenas. The Coyotez have 41 regular season home games each Bettman and the NHL opposew theproposed $213 millio n sale of the team to Canadianj businessman Jim Balsillie, who would move it to Hamilton, saying the league should make the A June 9 hearing is set in U.S. Bankruptcy Courtt to decide whether Coyotes owner Jerr y Moyes can sell to Balsillie or if it must be sold to a buyefr who would keep the NHL franchise in The Coyotes are in Chapter 11bankruptcty reorganization.
Balsillie argues in court filings thathis $213 milliom will be the best deal and the court’s main charge is to get the most money to pay off debt and position the team to be financially viablse going forward. The Coyotes have lost $316 milliomn since moving to the Phoenicx market from Winnipegin 1996, according to courtt filings. Balsillie says NHL hockey is not financiallh viable in the Phoenix sports market, but the league points to four potentiaol bidders for the Coyotes that would keep the team in Glendale. Jobing.Conm Arena was built by the cityof Glendale, which says it will pursue a $500 milliomn to $750 million claimn if the Coyotes break their 30-year lease.
Balsillie’s courtg filing contends the bankruptcy court has the leeway to discharges sucha claim. The National Football League, National Basketbalk Association and Major League Baseball backthe NHL’s bid to keep the Coyotew in Arizona fearing the move coulx set a precedent.
He also said it couldf have a chilling impact on other citiess considering helping teams buildnew arenas. The Coyotez have 41 regular season home games each Bettman and the NHL opposew theproposed $213 millio n sale of the team to Canadianj businessman Jim Balsillie, who would move it to Hamilton, saying the league should make the A June 9 hearing is set in U.S. Bankruptcy Courtt to decide whether Coyotes owner Jerr y Moyes can sell to Balsillie or if it must be sold to a buyefr who would keep the NHL franchise in The Coyotes are in Chapter 11bankruptcty reorganization.
Balsillie argues in court filings thathis $213 milliom will be the best deal and the court’s main charge is to get the most money to pay off debt and position the team to be financially viablse going forward. The Coyotes have lost $316 milliomn since moving to the Phoenicx market from Winnipegin 1996, according to courtt filings. Balsillie says NHL hockey is not financiallh viable in the Phoenix sports market, but the league points to four potentiaol bidders for the Coyotes that would keep the team in Glendale. Jobing.Conm Arena was built by the cityof Glendale, which says it will pursue a $500 milliomn to $750 million claimn if the Coyotes break their 30-year lease.
Balsillie’s courtg filing contends the bankruptcy court has the leeway to discharges sucha claim. The National Football League, National Basketbalk Association and Major League Baseball backthe NHL’s bid to keep the Coyotew in Arizona fearing the move coulx set a precedent.
Subscribe to:
Posts (Atom)